Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops bizaxofusp (MDNA55), an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a masked bi-functional anti-PD1-IL2 Superkine for various solid tumors; and MDNA132, an IL-13 Superkine for various tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, inhibitors, antibodies, cytokines, or other Superkines Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
| 1.83 | |
| 2.6 | |
| - | |
| 2.26 | |
| 2.74 | |
| 0.215-2.98 | |
| 180 M | |
| 76 433 K | |
| 0 | |
| -0.05 | |
| 1.206 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
The Canadian market has shown robust performance, rising by 1.6% over the past week and 25% over the last year, with earnings projected to grow annually by 16%. In this thriving environment, identifyi...
The Canadian market has seen a positive trend recently, climbing 1.6% in the last week and 25% over the past year, with earnings forecasted to grow by 16% annually. In this thriving environment, stock...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
